Finally, recognizing the limitations of inhaled CO gas delivery to acute indications where therapy can be delivered under close medical supervision, Proterris, in collaboration with its advisors, possesses and is developing broad libraries of novel, small molecule CO-releasers. Our portfolio comprises some of the industry’s most diverse scaffolds, many of which can be (and in many cases, already have been) combined with a variety of formulation, conjugation and tissue targeting technologies in order to tailor CO delivery to specific tissues and diseases.
As one particularly relevant example, a unique immuno-oncology (“I-O”) mechanism of action completely orthogonal to any I-O mechanism previously described has been discovered and characterized using a CO-protein conjugate possessing the following phenotypic properties:
Significant single agent activity Synergistic with check-point inhibitor therapy Generates durable immunologic memory Synergistic with chemotherapyWe aim to develop these small-molecule releasers for transplant, nephrology and respiratory indications where chronic dosing is required, and for a wide variety of oncology applications separately.
